Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
188
resultados
Última actualización
26/04/2026 [06:52:00]
Resumen de: WO2026082012A1
The present invention provides a drug-loaded nanoparticle composition suitable for drug delivery in vivo, wherein the drug-loaded nanoparticle composition is formed in the form of a non-covalent bond and comprises an active ingredient, cyclodextrin, and albumin. Drug-loaded nanoparticles or the composition thereof in the present invention are stable in a solution state, avoiding cumbersome operations of reconstitution and redissolution. Compared with a known freeze-dried powder of nanoparticles containing albumin, the nanoparticles in the present invention have a particle size of less than 150 nm, can remain stable for at least 7 days or more without change, and can be predicted to be stable for a long time.
Resumen de: AU2024362372A1
When a biological material sensitive to an external reaction is incorporated during hydrogel production, physical stimulation or chemical stimulation applied in conventional hydrogel production methods requires a sophisticated process and can affect the activity and structure of particles in the hydrogel. On the other hand, a hydrogel using an aqueous-two phase system and a method for producing same provided by the present invention can simultaneously achieve hydrogel formation and the encapsulation of desired nanoparticles in the hydrogel. The present invention has succeeded in simply concentrating desired nanoparticles in a hydrogel with a high yield. In addition, the present invention relates to a hydrogel using an aqueous-two phase system and a method for producing same, wherein concentration and hydrogel formation are simultaneously performed, and thus the time for producing the hydrogel is reduced and the cost is significantly reduced.
Resumen de: WO2026084314A1
The present invention relates to: lipid nanoparticles with improved genetic material delivery efficiency through the regulation of an extracellular matrix and pH control of intracellular organelles; and use thereof. A composition for delivering a genetic material, according to the present invention, comprises lipid nanoparticles and a proton pump inhibitor, whereby the genetic material can be effectively delivered by overcoming various intracellular and extracellular barriers and the limitations of existing delivery systems.
Resumen de: WO2026085319A1
The present disclosure relates, in one aspect, to degradable ionizable lipid compounds of formula (I). In another aspect, the disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid of formula (I). In another aspect, the disclosure provides methods of the LNPs of the disclosure for splenic delivery of therapeutic cargo.
Resumen de: WO2026085256A1
The present disclosure relates to lipids and compositions thereof. In various aspects of the disclosure, the compositions are lipid nanoparticle compositions that are used as adjuvants used with vaccines, such as RNA vaccines, and/or to prevent or treat diseases or disorders in a subject in need thereof.
Resumen de: US20260108536A1
Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.
Resumen de: US20260108539A1
This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection. The composition includes phytocannabinoids such as CBG and CBC, along with hyaluronic acid, type II collagen, and calcium gluconate, embedded within a nanoplatform designed to enhance bioavailability and ensure controlled release in the synovial space. Tailored for osteoarthritis patients, the treatment alleviates joint pain, stiffness, reduced mobility, inflammation, sensations of friction, muscle weakness, and joint deformity. Cannabinoids act through multiple mechanisms, including interaction with CB1 and CB2 receptors, cytokine modulation, inhibition of NF-κB, and activation of the TRPV1 receptor, providing a potent anti-inflammatory effect. The formulation aims to halt cartilage degeneration, reduce pain, and slow osteoarthritis progression. The production process uses nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration, ensuring both efficacy and safety.
Resumen de: WO2026084761A2
Disclosed are lipid nanoparticle formulations comprising a lipidoid as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses a pharmaceutical composition comprising a lipidoid composition of the invention.
Resumen de: US20260108475A1
Methods for inserting a targeting moiety (such as an antigen-binding protein moiety, a fragment antigen-binding moiety, or the like) into a lipid nanoparticle and compositions resulting from such methods are provided. The methods generally utilize a reaction that forms targeted nanoparticles by combining a targeting moiety and a lipid nanoparticle. A quenching operation is then provided by cooling the reaction to a temperature that stops the insertion of the targeting moiety. The reaction substantially preserves the integrity of a nucleic acid cargo (such as an mRNA encoding a VHH binding molecule).
Resumen de: WO2026082856A1
The invention relates to a composition for use in the treatment or prevention of one or more unwanted immune responses in a subject, wherein the one or more unwanted immune responses are caused by the use of one or more immunogenic drugs and wherein the composition comprises negatively charged non-polymeric nanoparticles, wherein the negatively charged non-polymeric nanoparticles are selected from the group consisting of at least one of silicon particles, solid lipid particles comprising at least one immune modulating drug and liposomes comprising at least one immune modulating drug.
Resumen de: US20260108622A1
Provided herein are non-PEGylated lipid nanoparticles comprising an outer polyanionic layer, compositions thereof, and methods of using said particles or compositions for therapeutic applications.
Resumen de: US20260108463A1
The present invention relates to a composition comprising an oil in water nanoemulsion and a highly lipophilic macrolide lactone as active agent, such as tacrolimus, dissolved in the nanoemulsion. In this formulation, tacrolimus can be fully dissolved, rather than suspended, and shows an improved stability in terms of active substance content, pH, particle size and particle size homogeneity.
Resumen de: WO2026084669A1
The present invention is directed to polymer-drug conjugates and/or compositions and/or nanoparticles comprising anti-cancer agents. The present invention is also directed to polymer- drug conjugates and/or compositions comprising docetaxel and the administration of docetaxel derivatives for the treatment of a number of diseases. The present invention is also directed to polymer-drug conjugates and/or compositions comprising gemcitabine or combretastatin A4 for the treatment of a number of diseases.
Resumen de: US20260108577A1
A method of preparing biotic super-paramagnetic nanoparticles can include combining a Colchicum ritchii plant extract with a ferric chloride solution to provide a mixture and adding sodium hydroxide solution to the mixture to provide the super-paramagnetic nanoparticles.
Resumen de: US20260108538A1
Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.
Resumen de: US20260108537A1
This disclosure describes a cannabinoid-based nanoplatform for treating shingles, designed to enhance bioavailability and controlled release of active ingredients. The composition includes cannabinoids like cannabidiol (CBD) and cannabigerol (CBG), alongside flavonoids, polyphenols, and alkaloids, in oral and topical formulations. The oral capsule combines cannabinoids with polyphenols and flavonoids to provide systemic anti-inflammatory, antiviral, and neuroprotective effects, particularly for nerve pain and inflammation, including postherpetic neuralgia. The topical cream includes cannabinoids, capsaicin, and aloe vera, offering localized relief from pain, itching, and rash. The method targets both systemic and localized symptoms during the acute phase of shingles, aiming to inhibit varicella-zoster virus replication, disrupt viral assembly, and prevent viral release, while also providing immune modulation and anti-inflammatory benefits. The nanoplatform uses nano-emulsification techniques, producing particles smaller than 200 nm to ensure optimal delivery and therapeutic efficacy, offering comprehensive relief for shingles symptoms.
Resumen de: WO2026082030A1
Provided in the present invention is an ionizable lipid compound. Specifically, the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof. Further provided in the present invention are a nanoparticle pharmaceutical composition containing the compound, and the use of the compound and composition thereof in the delivery of nucleic acids.
Resumen de: WO2026083169A2
The present invention relates to natural nanocarriers or nanoparticles with biocompatible, biodegradable, hypoallergenic, environmentally and physiologically acceptable properties. More in particular, it can be stated that the present invention relates to natural biopolymer nanocarriers, nanoparticles or nano-spheres with biocompatible, biodegradable, environmentally and physiologically acceptable properties as vehicles for physiological and environmentally safe delivery of active ingredients. The present invention also relates to nanoparticle compositions, methods of making the nanoparticles and nanoparticles compositions, as well as uses thereof.
Resumen de: WO2026083241A1
The present disclosure provides ionizable lipids that are particularly beneficial in formulations of lipid nanoparticles providing advantageous improvements in the delivery of nucleic acids to hepatic stellate cells with enhanced efficiency. The ionizable lipids are N,N-substituted hydroxylamine ester compound. The disclosure also provides lipid nanoparticles, pharmaceutical compositions, and methods including the provided ionizable lipids.
Resumen de: US20260108472A1
0000 Disclosed are methods and compositions for restoring Cyr61 in bone tissue. In certain aspects, the compositions comprise a recombinant Cyr61 carried in carbon nanotubes. The compositions may be used for various methods including restoring Cyr61 expression in bone, increasing bone density, or treating a bone disease in a patient.
Resumen de: US20260109984A1
0000 Therapeutic methods, systems, and compositions for treating a patient suffering from hemoglobinopathy include treating the patient to increase expression of noncoding RNA activated by DNA damage (NORAD). Overexpression of NORAD long non-coding RNA leads to an increase in fetal hemoglobin expression. The hemoglobinopathy may be β-thalassemia or sickle cell disease.
Resumen de: WO2026085500A1
Provided herein are compositions and methods for ablating intracellular signaling through specific cell surface receptors as means of treatment for various conditions of a pro-inflammatory character. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint. In some aspects, the compositions and method are for treating or preventing localized nociception, inflammation, degeneration, or morphological changes associated with back or spine conditions or disorders.
Resumen de: WO2026085291A1
Disclosed herein are metabolizable binary gold supraclusters, which, in some implementations, comprise cationic gold nanoclusters laden with a therapeutic nucleic acid, such as a small interfering RNA (siRNA), and are intertwined through bioresponsive crosslinkers within a hydrophilic polymer matrix. Also provided herein are uses of the supraclusters, e.g., in treatment of diseases such as cancers.
Resumen de: WO2026085498A1
The present disclosure provides compositions and methods for enhancing gene editing. In some aspects, the compositions and methods are used prevent the progression or treat diseases such as osteoarthritis and other joint disorders that are characterized by an inflammatory component.
Nº publicación: WO2026081389A1 23/04/2026
Solicitante:
SICHUAN UNIV [CN]
\u56DB\u5DDD\u5927\u5B66
Resumen de: WO2026081389A1
The present invention relates to the field of pharmaceutical technology, and in particular, to a daptomycin nano-FORMULATION, a method for preparing same, and use thereof. The method comprises: A, encapsulating daptomycin with a copolymer poly(lactic-co-glycolic acid) to give a nanoparticle (NP); and B, sonicating a cell membrane vesicle overexpressing RANK and the nanoparticle (NP) in a water bath for 3 min, and then sequentially extruding the mixture through polycarbonate membranes of 800 nm, 400 nm, and 200 nm to give the daptomycin nano-formulation. The weight ratio of the membrane protein to PLGA is 0.25. By the method of the present invention, a daptomycin nano-formulation targeting rheumatoid arthritis is successfully prepared. The daptomycin nano-formulation prepared by the present invention has good stability. The daptomycin nano-formulation of the present invention has good therapeutic effects against RA.
BOPI
Sede Electrónica
